Antiviral diseases

May 9, 2020

Hypertonic saline-based Prophylatic therapy for SARS-COV-2/COVID-19: Hypertonic saline (Nacl) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, Respiratory Syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 10/May/2020, 12.50am

April 14, 2020

Hyperthermia-based Prophylatic therapy against SARS-COV-2/COVID-19: Hyperthermia (40C to 43C) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 15/April/2020, 12.27 am

April 12, 2020

A potential vaccine against SARS-COV-2: Repurposing the IB-ND Virus-like particles (VLPs) vaccine  into a Prophylactic IB-ND VLPs-COVID-19 vaccine: A novel chimeric infectious bronchitis-Newcastle disease (IB-ND) virus-like particles (VLPs) inhibit SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 12/April/2020, 11.01 pm

April 5, 2020

A vaccine against SARS-COV-2: Repurposing the Influenza A (H1N1)/Flu vaccine into a Prophylactic Flu-COVID-19 vaccine: Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 5/April/2020, 3.14 pm